9000余名银屑病患者中HLA-C*06:02携带者组间临床特征与共病负担的差异
研究基于英国两个横断面数据集(观察性严重银屑病研究n=3767;UK Biobank银屑病人群n=5519),比较欧洲裔HLA-C*06:02阳性与阴性银屑病患者的临床特征。HLA-C*06:02阳性与更早发病年龄相关,并在女性中与疾病表现度相关;HLA-C*06:02阴性则与大型斑块、甲受累、更高的中心性肥胖及其他心脏代谢共病相关。
要点
- HLA-C*06:02阳性与银屑病发病年龄更早相关,并证实与女性疾病表现度相关。
- HLA-C*06:02阴性与大斑块疾病(OR=0.73)和甲受累(OR=0.70)相关。
- HLA-C*06:02阴性者中心性肥胖更明显,女性尤为显著,且其他心脏代谢共病患病率更高。
核心结论
- HLA-C*06:02状态可界定具有临床相关性的银屑病内型,支持其作为未来多标志物分层医疗中重要生物标志物的潜力。
研究设计与样本
- 研究采用两个英国横断面数据集:观察性严重银屑病研究(Biomarkers of Systemic Treatment Outcomes in Psoriasis,n=3767)和大型人群生物资源库UK Biobank(含银屑病患者n=5519)。
- 比较欧洲裔HLA-C*06:02阳性(携带一个或两个拷贝)与HLA-C*06:02阴性(无拷贝)个体的 demographic、环境和临床变量。
- 使用多变量回归分析校正事先设定的中介效应。
主要发现
- HLA-C*06:02阳性与银屑病发病年龄更早相关(确认既往观察)。
- HLA-C*06:02阳性与女性疾病表现度相关:Biomarkers of Systemic Treatment Outcomes in Psoriasis中P=2.7×10⁻¹⁴,UK Biobank中P=1.0×10⁻⁸。
- HLA-C*06:02阴性与大斑块疾病相关(OR=0.73,P=7.4×10⁻⁴),与甲受累相关(OR=0.70,P=2.4×10⁻⁶)。
- HLA-C*06:02阴性者中心性肥胖更高:Biomarkers of Systemic Treatment Outcomes in Psoriasis中腰围差异2.0 cm(P=8.4×10⁻⁴),UK Biobank中腰围差异1.4 cm(P=1.5×10⁻⁴),女性尤为显著。
- HLA-C*06:02阴性者其他心脏代谢共病患病率更高。
关键数值与推荐
- HLA-C*06:02阳性定义为携带一个或两个HLA-C*06:02等位基因拷贝;阴性定义为无拷贝。
- 大斑块疾病与HLA-C*06:02的OR=0.73(P=7.4×10⁻⁴);甲受累与HLA-C*06:02的OR=0.70(P=2.4×10⁻⁶)。
- 腰围差异:Biomarkers of Systemic Treatment Outcomes in Psoriasis中2.0 cm(P=8.4×10⁻⁴),UK Biobank中1.4 cm(P=1.5×10⁻⁴)。
- 女性疾病表现度关联P值:Biomarkers of Systemic Treatment Outcomes in Psoriasis P=2.7×10⁻¹⁴,UK Biobank P=1.0×10⁻⁸。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The identification of robust endotypes-disease subgroups of clinical relevance-is fundamental to stratified medicine. We hypothesized that HLA-C∗06:02 status, the major genetic determinant of psoriasis, defines a psoriasis endotype of clinical relevance. Using two United Kingdom-based cross-sectional datasets-an observational severe-psoriasis study (Biomarkers of Systemic Treatment Outcomes in Psoriasis; n = 3,767) and a large population-based bioresource (UK Biobank, including n = 5,519 individuals with psoriasis)-we compared demographic, environmental, and clinical variables of interest in HLA-C∗06:02-positive (one or two copies of the HLA-C∗06:02 allele) with those in HLA-C∗06:02‒negative (no copies) individuals of European ancestry. We used multivariable regression analyses to account for mediation effects established a priori. We confirm previous observations that HLA-C∗06:02-positive status is associated with earlier age of psoriasis onset and extend findings to reveal an association with disease expressivity in females (Biomarkers of Systemic Treatment Outcomes in Psoriasis: P = 2.7 × 10-14, UK Biobank: P = 1.0 × 10-8). We also show HLA-C∗06:02-negative status to be associated with characteristic clinical features (large plaque disease, OR for HLA-C∗06:02 = 0.73, P = 7.4 × 10-4; nail involvement, OR = 0.70, P = 2.4 × 10-6); higher central adiposity (Biomarkers of Systemic Treatment Outcomes in Psoriasis: waist circumference difference of 2.0 cm, P = 8.4 × 10-4; UK Biobank: waist circumference difference of 1.4 cm, P = 1.5 × 10-4), especially in women; and a higher prevalence of other cardiometabolic comorbidities. These findings extend the clinical phenotype delineated by HLA-C∗06:02 and highlight its potential as an important biomarker to consider in future multimarker stratified medicine approaches.
引用
- Douroudis K, Ramessur R, Barbosa IA, et al. Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis. J Invest Dermatol. 2021. PMID: 34767815. doi:10.1016/j.jid.2021.08.446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。